GlycoMimetics, Inc. Awarded National Institutes of Health (NIH) Grant to Study Drug Candidate in Diabetes

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced it has been awarded a grant from The National Heart, Lung, and Blood Institute (NHLBI) of The National Institutes of Health (NIH) to evaluate its E-selectin small molecule antagonists in animal models of vascular complications of diabetes.